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Abstract
Background
Serine proteases are important virulence factors for many pathogens. Recently, we dis-
covered a group of trypsin-like serine proteases with domain organization unique to flat-
worm parasites and containing a thrombospondin type 1 repeat (TSR-1). These
proteases are recognized as antigens during host infection and may prove useful as
anthelminthic vaccines, however their molecular characteristics are under-studied. Here,
we characterize the structural and proteolytic attributes of serine protease 2 (SmSP2)
from Schistosoma mansoni, one of the major species responsible for the tropical infec-
tious disease, schistosomiasis.
Methodology/Principal findings
SmSP2 comprises three domains: a histidine stretch, TSR-1 and a serine protease
domain. The cleavage specificity of recombinant SmSP2 was determined using posi-
tional scanning and multiplex combinatorial libraries and the determinants of specificity
were identified with 3D homology models, demonstrating a trypsin-like endopeptidase
mode of action. SmSP2 displayed restricted proteolysis on protein substrates. It acti-
vated tissue plasminogen activator and plasminogen as key components of the fibrino-
lytic system, and released the vasoregulatory peptide, kinin, from kininogen. SmSP2
was detected in the surface tegument, esophageal glands and reproductive organs of
the adult parasite by immunofluorescence microscopy, and in the excretory/secretory
products by immunoblotting.
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Conclusions/Significance
The data suggest that SmSP2 is secreted, functions at the host-parasite interface and con-
tributes to the survival of the parasite by manipulating host vasodilatation and fibrinolysis.
SmSP2 may be, therefore, a potential target for anti-schistosomal therapy.
Author summary
Schistosomiasis (bilharziasis) is a global parasitic infection with more than 240 million
people infected. It is caused by Schistosoma flatworms that live in the bloodstream. Cur-
rent treatment relies on one drug, and no effective vaccine has yet been developed. Proteo-
lytic enzymes (proteases) help the parasite survive in the mammalian host, allowing the
schistosome to invade, feed, grow, reproduce and, manipulate the immune system. Thus,
proteases are considered potential drug and vaccine targets. We previously described, and
herein, investigate at the protein level, SmSP2, the major serine protease produced by the
blood-dwelling stages of S. mansoni. We show that SmSP2 is secreted by the parasite and
effectively processes host blood bioactive peptides and proteins that are involved in fibri-
nolysis and regulation of vascular tone. We propose, therefore, that SmSP2 modulates
host hemostasis to promote parasite infection and survival. Thus, SmSP2 and similar pro-
teins in other parasitic flatworms represent potential targets for novel drug or vaccine
interventions.
Introduction
Schistosomiasis (bilharziasis) is a chronic infectious disease caused by a trematode blood flukes
of the genus Schistosoma. A public health problem in 74 developing countries, the parasite
infects over 240 million people with up to 700 million people at risk [1, 2]. Adult schistosomes
can reside for decades in the host vascular system as male-female pairs producing hundreds of
eggs per day [3]. Morbidity arises from immuno-pathological reactions to and entrapment of
schistosome eggs in various tissues [4]. In the absence of a vaccine, treatment and control of
schistosomiasis relies on a single drug, praziquantel (PZQ) [5, 6]. During its complex life cycle,
the parasite survives in various environments by presenting or releasing bioactive molecules
that aid survival and modulate host physiology [7–10]. Disruption of these potential mecha-
nisms by specific drugs or vaccines may provide therapeutic benefits.
Proteolytic enzymes (proteases) of schistosomes [11] are attractive drug targets as they fre-
quently operate at the host–parasite interface, and facilitating parasite invasion, migration,
nutrition and immune evasion [12–14]. Most studies on schistosome proteases, to date, have
focused on cysteine and aspartic proteases that contribute to the digestion of the blood meal
[15, 16]. Among them, the cathepsin B1 of S. mansoni (SmCB1) has been validated in a murine
model of schistosomiasis as a chemotherapeutic target [17], and small molecule inhibitors of
SmCB1 are under investigation as potential drug leads [18–20].
Schistosome serine proteases (SPs) are less studied with the exception of cercarial elastase,
which facilitates penetration of the human host by infective larvae [21, 22]. Recently, we
uncovered a repertoire of S. mansoni trypsin- and chymotrypsin-type S1 family serine prote-
ases (SmSPs) by employing a series of genomic, transcriptomic, proteolytic and phylogenetic
investigational strategies [23]. Among these, SmSP2 is the most abundantly expressed in
blood-dwelling stages [23]. Interestingly, SmSP2 ortholog (mastin) was identified as potential
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vaccine targets in Schistosoma haematobium based on IgG1 immune response of individuals
with drug-induced resistance [24].
In this study, we report the first detailed biochemical and enzymatic characterization of
SmSP2. This enzyme processes several proteins and peptides that are involved in host proteo-
lytic cascades, i.e., blood coagulation, fibrinolysis and blood pressure regulation, and, thus,
may interfere with critical vascular hemostatic processes. Accordingly, SmSP2 may be a target
for novel anti-schistosomal therapeutics.
Materials and methods
Ethics statement
Research with experimental animals was performed in accordance with the animal welfare
laws of the Czech Republic and in accordance with European regulations for transport, hous-
ing and care of laboratory animals (Directive 2010/63/EU on the protection of animals used
for scientific purposes). The project of experiments including the use of experimental animals
for present study was approved by Ministry of education, youth and sports of the Czech
Republic (approval number MSMT—7063/2017-2). All the animals used in the study were
maintained by certified person (certificate number CZ 02627) in specifically accredited labora-
tories of Institute of Immunology and Microbiology of the First Faculty of Medicine, Charles
University and the General University Hospital in Prague (accreditation number 70030/
2013-MZE-17214), both issued by the Ministry of Agriculture of the Czech Republic.
Schistosome material
Schistosoma mansoni (a Puerto Rican isolate) was routinely maintained in the laboratory by
cycling between the intermediate snail host, Biomphalaria glabrata, and outbred ICR mice as
definitive hosts. Infective larvae (cercariae) were released after light stimulation from infected
snails placed in fresh water. Adult mice were infected by immersing the feet and tails for 45
min in 50 ml of water containing approximately 500 cercariae. Six weeks post infection, mice
were euthanized by an intra-peritoneal injection of ketamine (Narkamon 5% - 1.2 mL/kg bw)
and xylazine (Rometar 2% - 0.6 mL/kg bw) and the worms recovered from the portal vein by
transcardial perfusion with RPMI 1640 medium as described previously [25–27]. Newly trans-
formed schistosomula (NTS) were prepared by mechanically transforming cercariae and culti-
vated in a Basch Medium 169 [28] containing 5% fetal calf serum, 100 units/mL penicillin and
100 μg/mL streptomycin for 5 days at 37˚C under a 5% CO2 atmosphere.
Preparation of schistosome extract, excretory/secretory products collection
and purification of native SmSP2
Soluble protein extracts (1–3 mg protein/mL) from S. mansoni adults were prepared by
homogenization in 50 mM Tris-HCl, pH 8.0, containing 1% CHAPS, 1 mM EDTA, 1 μM pep-
statin and 1 μM E-64 on an ice bath. The extract was cleared by centrifugation (16,000 g at 4˚C
for 10 min), ultra-filtered using a 0.22 μm Ultrafree-MC device (Millipore) and stored at
-80˚C. Excretory/secretory products (ESP) of adult worms were collected as described previ-
ously [29]. Specifically, fifty pairs of adult worms were washed five times in Basch medium 169
containing 5% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin and 1% Fun-
gizone (Gibco), incubated for 1h at 37˚C under a 5% CO2 atmosphere, washed five times and
then incubated overnight at 37˚C in 5% CO2 in the above medium supplemented with 5% fetal
calf serum but in the absence of Fungizone. Parasites were washed three times in the above
medium and then washed 10 times in M-199 medium containing 100 U/ml penicillin and
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100 μg/ml streptomycin, but without serum. Adults were evenly distributed in 5 ml of the
same medium in a 6-well cultivation dish and incubated for 16 h at 37˚C in 5% CO2. Medium
containing ESP was removed, filtered over an Ultrafree-MC 0.22 μm filter (Millipore), buffer
exchanged into ice-cold PBS, concentrated to 2 mL using Amicon Ultracel-10K filters (Milli-
pore) and aliquots stored at -80˚C.
Native SmSP2 was purified from the adult schistosome extract using Ni2+ chelating chro-
matography (Hi-Trap IMAC FF column, GE Healthcare Life Sciences) under native condi-
tions. The bound material was eluted using a 0.5 M imidazole and the purified proteins
analyzed by immunoblotting with anti-SmSP2 IgG.
Expression and purification of recombinant SmSP2 in Pichia pastoris
The full-length SmSP2 gene (GenBank KF510120; GeneDB Smp_002150) without the N-ter-
minal signal sequence predicted by SignalP [30] was codon-optimized for expression in P. pas-
toris and cloned into the pUC57 vector (GenScript) with an incorporated C-terminal His-tag
(GPHHHHHH). The SmSP2 protease domain (residues 201 to 501, Fig 1) containing a short
N-terminal propeptide (residues 183 to 200, Fig 1) was prepared by PCR amplification of the
synthetic SmSP2 gene using the forward primer, 5´-AAGAGAGGCTGAAGCTGCAAACTT
GACAAACACCTGTGGTATCAG-3´ that contained a Pst I restriction site, and the reverse
primer, 5´-GGCCACGTGAATTCCTTAGTGATGGTGATGGTGATGAGGACC-3. Both
primers contained 15 nucleotide extensions (underlined) homologous to the ends of Pst I-line-
arized pPICZαB vector (Thermo Fisher). The PCR product was cloned into this expression
vector using the In-Fusion HD Cloning Kit according to manufacturer protocol (Clontech)
and verified by DNA sequencing. Transformation of P. pastoris X-33 cells (Thermo Fisher)
and protein expression were carried out as described previously [31, 32].
The yeast medium containing recombinant SmSP2 was centrifuged (3,000 g for 10 min),
and the supernatant filtered (0.45 μm), lyophilized and dissolved in 20 mM MES buffer, pH
6.0 (to 10% of the original volume). The solution was then desalted over a Sephadex G-25 col-
umn equilibrated with the same buffer. SmSP2 was purified using chromatography on a
HiTrap Benzamidine FF column (GE Healthcare Life Sciences) equilibrated with 50 mM Tris-
HCl, pH 8.0, containing 0.5 M NaCl, and eluted with 50 mM glycine, pH 3.0. The pH of the
eluted fractions containing SmSP2 was adjusted to 6.0 by addition of 1M Tris-HCl, pH 8.0,
and enzyme fractions were stored in -80˚C. The purification process was monitored with a
kinetic activity assay using the fluorogenic substrate, P-F-R-AMC (AMC, 7-amino-4-methyl-
coumarin), and by SDS-PAGE and Western blotting.
Expression, refolding, purification of recombinant SmSP2 in E. coli
The Champion pET directional expression kit (Thermo Fisher) was selected for bacterial
expression of the SmSP2 protease domain (residues 201–501) that contained a short N-termi-
nal propeptide (residues 183 to 200, Fig 1). The 957 bp ORF was PCR amplified from a syn-
thetic SmSP2 gene using specific forward (5´- caccATGAATCTAACTAATACATGTGGAA
TACGTAAATCA-3´) and reverse (5´- AAATATTTTTGTTGCTAATTGTTTTGATATCC
AA-3´) primers. The PCR product was cloned into the expression vector pET100/D-TOPO
(Thermo Fisher) incorporating an N-terminal His tag and verified by DNA sequencing.
Recombinant SmSP2 was produced in E. coli BL21(DE3) (Thermo Fisher), purified from
inclusion bodies using Ni2+ chelating chromatography under denaturing conditions and the
purified protein was refolded using the dialysis protocol described in [33].
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Preparation of antibodies and immunoblotting
Specific polyclonal antibodies were generated in rabbits (Moravian Biotechnology) against the
bacterially-expressed SmSP2 protease domain. Antigen (50 μg in Freund’s incomplete adju-
vant) was administered three times each three weeks apart. IgG was isolated from the serum
by affinity chromatography with a HiTrap Protein A column (GE Healthcare Life Sciences)
according to the manufacturer’s protocol. Immunoselection of SmSP2-specific IgG was carried
out using a standard methodology [34]. Briefly, 800 μg of recombinant SmSP2 expressed in E.
coli was resolved by SDS-PAGE and transferred to polyvinylidene difluoride membrane.
Excised strips containing SmSP2 were blocked with 3% BSA in 50 mM Tris-HCl, pH 7.5, con-
taining 150 mM NaCl and 0.1% Tween (TTBS) for 1 h, washed with TTBS, and incubated with
the protein-A purified anti-SmSP2 IgG overnight at 4˚C. After washing, bound antibodies
were eluted with 100 mM glycine, pH 2.5 and the elution was immediately adjusted to pH 7.5
using 1 M Tris-HCl.
Fig 1. Domain organization and amino acid sequence of SmSP2. (A) Schematic diagram of the domain layout. The N-terminal signal
peptide, “His stretch’ (HS), thrombospondin type 1 repeat (TSR-1) and S1 family protease domains are depicted in blue, purple, green, and
red, respectively. Amino acid residue numbers are indicated. (B) The amino acid sequence of SmSP2 with the various domains color-coded
by underlining as in (A). Predicted N-glycosylation sites are highlighted in grey, and His residues in the His stretch are in purple. The
catalytic residues, His246, Asp311 and Ser447 are red-boxed; and Asp441 in the S1 subsite that accounts for trypsin-like activity is green-
boxed. Cys residues of the protease domain that are predicted to form a disulfide are indicated by the same color; Cys residues of the TSR-1
domain are colored yellow. The propeptide is underlined with dashed red line.
https://doi.org/10.1371/journal.pntd.0006446.g001
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For immunoblotting, adult schistosome homogenate (30 μg protein) and rSmSP2 (1 μg)
were resolved by SDS-PAGE (4–12% NuPAGE gel, Thermo Fisher) under reducing conditions
and transferred onto a PVDF membrane. The membrane was blocked for 1 h with 3% BSA in
TTBS, washed with TTBS and incubated overnight with anti-SmSP2 polyclonal IgG diluted
1:200 in TTBS. After washing with TTBS, the membrane was incubated for 1 h with goat
horseradish peroxidase-conjugated anti-rabbit IgG (Sigma-Aldrich) at a dilution of 1:10,000.
After washing with TTBS, the membrane was developed with Luminata Crescendo Western
HRP substrate (Merck) and imaged using an ImageQuant LAS 4000 biomolecular imager (GE
Healthcare Life Sciences).
Immunofluorescence microscopy
Adult S. mansoni males and females were carefully separated over ice, washed three times in
100 mM sodium phosphate, pH 7.4, containing 154 mM NaCl (PBS), fixed in Bouin’s solution
(Sigma-Aldrich) for 45 min at 25˚C, and embedded in paraffin blocks. Sections (6–8 μm each)
were deparaffinized in xylol, rehydrated in an ethanol series of decreasing ethanol concentra-
tion and boiled in a water bath in 10 mM sodium citrate, pH 6.0, for 15 min. Cooled sections
were rinsed with PBS, permeabilized in PBS containing 0.25% Triton X-100 (PBS/Triton) for
20 min, and blocked overnight at 4˚C with 2% BSA in PBS/Triton. After washing in PBS/Tri-
ton, the sections were incubated for 60 min at 4˚C with rabbit polyclonal anti-SmSP2 IgG
diluted 1:25 in PBS/Triton containing 1% BSA. Sections were then washed three times in PBS/
Triton and incubated for 30 min at 25˚C with anti-rabbit IgG Alexa 647-conjugated secondary
antibody (Thermo Fisher) diluted 1:500 in PBS/Triton. After washing with PBS/Triton, the
sections were mounted in Prolong Diamond antifade reagent containing DAPI (Thermo
Fischer). The fluorescence was visualized using an Olympus IX83 microscope equipped with
PCO edge 5.5 camera and CoolLED pE-4000 LED illumination system. DAPI signal was
detected using excitation diode 365 nm and emission filter 440/40 nm, Alexa 647 using diode
635 nm and emission filter 700/75. Appropriate lightning settings were determined using con-
trol slides probed with pre-immune serum to define the background signal threshold. Image
stacks of optical sections were processed using the Fiji software.
Active site labeling of SmSP2
Recombinant SmSP2 expressed in P. pastoris (1 μg) was incubated 1 h at 37˚C with 1 μM activ-
ity-based probe BoRC [35] in 50 mM Tris-HCl, pH 8.0. The competitive labeling reaction was
also performed after treatment of SmSP2 for 15 min at 37˚C with 1 mM serine protease inhibi-
tor Pefabloc SC (Sigma-Aldrich). The labeled SmSP2 was precipitated with acetone, resolved
by SDS-PAGE, and visualized in-gel using a Typhoon 9410 imager (GE Healthcare) as
described previously [36].
Kinetic SmSP2 activity and inhibition assays
SmSP2 activity was measured in continuous kinetic assays using the following peptidyl fluoro-
genic AMC substrates (Bachem): Z-F-R-AMC (Z, Benzyloxycarbonyl), Bz-F-V-R-AMC (Bz,
Benzoyl), P-F-R-AMC, Boc-L-R-R-AMC (Boc, t-Butyloxycarbonyl), Boc-Q-A-R-AMC, Boc-
V-L-K-AMC, Suc-A-A-F-AMC (Suc, Succinyl), Suc-A-A-P-F-AMC, MeOSuc-A-A-P-V-AMC
(MeOSuc, 3-Methoxysuccinyl), Z-G-G-L-AMC, Z-V-K-M-AMC, Boc-L-G-R-AMC,
Z-V-V-R-AMC, V-P-R-AMC, Z-R-R-AMC, R-R-AMC, R-AMC and Boc-L-L-V-Y-AMC.
Assays were performed at 37˚C in white 96-well microplates in a total volume of 100 μl.
Recombinant SmSP2 expressed in P. pastoris (10 ng) was pre-incubated for 10 min at 37˚C in
80 μl of 0.1 M Tris-HCl, pH 8.0. The reaction was initiated by adding 20 μl of substrate
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solution (50 μM final concentration) in the same buffer. Proteolytic activity was measured con-
tinuously in an Infinite M1000 microplate reader (Tecan) at excitation and emission wave-
lengths of 360 and 465 nm, respectively. The pH activity profile was determined in 50 mM
citrate, 100mM phosphate (pH range 3.0–7.5), and 0.1M glycine (pH range 8.0–11.0) using the
P-F-R-AMC substrate. The pH profile of SmSP2 activity in schistosome homogenates (1–5 μg
of protein) was measured analogously, but in the presence of 10 μM E-64 and 1 mM EDTA to
prevent undesired proteolysis by cysteine proteases and metalloproteases, respectively. Prote-
ase activity was expressed as the remaining portion that was sensitive to 1 mM Pefabloc SC.
For inhibition measurements, inhibitors were added to the 80 μL pre-incubation solution at
the final concentrations listed in Table 1. After 10 min at 37˚C, reactions were initiated by the
addition of substrate. For pH stability determinations, SmSP2 was incubated in 50 mM citrate,
100mM phosphate (pH range from 3.0 to 7.0) or 0.1M glycine (pH range from 8.0 to 11.0).
After 1, 4 and 20 h, aliquots containing 10 ng SmSP2 were taken and SmSP2 activity was mea-
sured using P-F-R-AMC as described above. All measurements were done in triplicate.
Interaction of SmSP2 with protein substrates
Recombinant SmSP2 expressed in P. pastoris (300 ng) was incubated at 37˚C with 1–20 μg of
human plasminogen (hPLG, R&D Systems), high molecular weight human plasma kininogen
(HMWK; Merck), human tissue plasminogen activator (tPA), human serum albumin (HSA),
human hemoglobin, calf collagen type I, human fibronectin and rabbit immunoglobulin G (all
Sigma-Aldrich) in 25 μL 100 mM Tris-HCl, pH 8.0. After incubation (between 1 and 48 h), the
reaction was stopped by adding Pefabloc SC (final concentration 1 mM) and 20 μl of the
Table 1. Sensitivity of rSmSP2 to protease inhibitors.
Inhibitora Target proteaseb Concentration (μM) Inhibition (%)c
Pefabloc SC SP 1000 100
Benzamidine SP 1000 100
3,4-dichlorcoumarin SP 100 71.4 ± 3.3
Antipain SP, CP 20 100
Leupeptin SP, CP 20 100
BPTI (Aprotinin) SP 10 87.0 ± 2.6
STI SP 10 91.8 ± 0.9
α-1-antichymotrypsin SP 1 13.2 ± 2.4
α-1-antitrypsin SP 1 79.0 ± 0.9
Antithrombin III SP 1 99.1 ± 0.3
PAI-1 SP 1 100
E-64 CP 10 7.2 ± 0.9
Pepstatin A AP 1 0
EDTA MP 1000 3.2 ± 0.9
Bestatin MP 1 4.5 ± 2.0
Phenanthroline MP 1000 26.9 ± 4.7
α-2-macroglobulin all types 0.1 61.6 ± 0.4
a Abbreviations: BPTI (bovine pancreatic trypsin inhibitor), STI (soybean trypsin inhibitor), E64 (trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane), PAI-1
(plasminogen activator inhibitor-1).
b The target proteases are classified based on catalytic type into aspartic (AP), cysteine (CP), serine (SP) proteases and metalloproteases (MP).
c rSmSP2 was pre-incubated with the given inhibitor and remaining activity was measured in a kinetic assay with the fluorogenic substrate P-F-R-AMC. The mean
values ± S.D. of three replicates are expressed as the percentage inhibition relative to uninhibited controls.
https://doi.org/10.1371/journal.pntd.0006446.t001
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reaction was resolved by SDS-PAGE (4-12% Nupage gel) and stained with Coomassie Brilliant
Blue G250. In control experiments, protein was incubated in the absence of SmSP2 and ana-
lyzed under identical conditions. Processing products generated during HMWK degradation
were identified by mass spectrometry, the reaction mixture was analyzed using LC-MS/MS as
described previously [32, 37]. To analyze the activation of hPLG and tPA by SmSP2, aliquots
of the reaction mixtures containing 100 ng of hPLG or tPA were withdrawn at different time
intervals and activity was measured in a kinetic assay using 50 μM Boc-V-L-K-AMC or
Z-G-G-R-AMC, respectively, in 100 mM Tris-HCl, pH 7.5, containing 100 mM NaCl. Proteo-
lytic activity was measured continuously as described above. In control experiments, SmSP2,
hPLG or tPA alone were analyzed under identical conditions.
Hydrolysis of peptide hormones by SmSP2
Extended bradykinin (Ac-SLMKRPPGFSPFRSSR-amide, Ac, acetyl) was synthesized as a pep-
tidyl amide by Fmoc solid phase chemistry in an ABI 433A peptide synthesizer (Applied Bio-
systems), as described previously [19, 38]. Recombinant SmSP2 expressed in P. pastoris (200
ng) was incubated at 37˚C for 1 to 16 h with 25 nmol of bradykinin, lysyl-bradikinin (kallidin),
vasopresin (all Sigma-Aldrich) or extended bradykinin in 0.1 M Tris-HCl, pH 8.0, in a total
volume of 50 μL. The reaction was stopped by adding TFA to a final concentration of 1%. The
resulting fragments were purified by reverse-phase HPLC using a Luna C18 column (25 x 0.46
cm, Phenomenex) and the TFA/acetonitrile system, and characterized by MS/MS [32, 37].
Hydrolysis of peptides by cultured schistosomes
Adult worms were washed and treated as described above (section Preparation of schistosome
extract, excretory/secretory products collection and purification of native SmSP2). Five adult
schistosome pairs were then placed into clear, 24-well, flat-bottom plates (Costar) containing
500 μL Basch Medium 199 [28], supplemented with 100 units/mL penicillin and 100 μg/mL
streptomycin (without fetal bovine serum). Human vasopressin or extended bradykinin
(10 μM) was added and the incubation continued for 16 h at 37˚C under a 5% CO2 atmo-
sphere. In control experiments, the peptides were incubated in the same system but in the
absence of schistosomes. After incubation, the samples were ZipTiped and the resulting frag-
ments were analyzed using MALDI-TOF performed on an UltrafleXtreme (Bruker Daltonik)
operated in reflectron mode with an acceleration voltage of 25 kV and a pulsed ion extraction
of 120 ns. Desorption and ionization were achieved using a Smartbeam II laser. α-Cyano-
4-hydroxycinnamic acid was used as a matrix. The data were acquired from m/z 220 to 3700
and analyzed with the FlexAnalysis 3.3 software (Bruker Daltonik). The mass spectra were
externally calibrated using a Peptide Calibration Standard I (Bruker Daltonik) and averaged
from 3000 laser shots.
Subsite profiling of SmSP2 by a positional scanning synthetic
combinatorial library (PS-SCL) and by multiplex cleavage assays
Synthesis of the PS-SCL has been previously described [39]. The assays were carried out in
black 96-well microplates in 0.1 M Tris-HCl, pH 8.0, containing 0.01% Tween 20 and initiated
by addition of recombinant SmSP2 (10 ng). Release of 7-amino-4-carbamoylmethylcoumarin
(ACC) was measured in an SpectraMax Gemini fluorescence spectrometer (Molecular
Devices) with excitation and emission wavelengths set to 380 and 460 nm, respectively.
The Multiplex Substrate Profiling by Mass Spectrometry (MSP-MS) assay was performed as
previously described [29]. SmSP2, human plasma kallikrein (Sigma-Aldrich) and bovine tryp-
sin Sigma-Aldrich) (all 17 nM) were incubated in triplicate with a mixture of 228 synthetic
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tetradecapeptides (0.5 uM each) in 10 mM Tris-HCl, pH 8.0. After 15, 60, and 240 minutes,
20 μL aliquots were removed, quenched with 6.4 M guanidinium chloride, immediately frozen
at -80˚C. Control reactions were performed by treating enzymes with guanidinium chloride
prior to peptide exposure. Samples were acidified to< pH 3.0 with 1% formic acid, desalted
with C18 LTS tips (Rainin), and injected into a Q Exactive Mass Spectrometer (Thermo)
equipped with an Ultimate 3000 HPLC (Thermo). Peptides separated by reverse phase chro-
matography on a C18 column (1.7 um bead size, 75 um x 25 cm, heated to 65˚C) at a flow rate
of 300 nL min-1 using a 55-min. linear gradient from 5% B to 30% B, with solvent A: 0.1% for-
mic acid in water and solvent B: 0.1% formic acid in acetonitrile. Survey scans were recorded
over a 150–2000 m/z range at 70000 resolutions (AGC target 1×106, 75 ms maximum). MS/
MS was performed in data-dependent acquisition mode with HCD fragmentation (30 normal-
ized collision energy) on the 10 most intense precursor ions at 17500 resolutions (AGC target
5×104, 120 ms maximum, dynamic exclusion 15 s).
Peak integration and peptide identification were performed using Peaks software (Bioinfor-
matics Solutions Inc.). Quantification data are normalized by LOWESS and filtered by 0.3 pep-
tide quality. Missing and zero values are imputed with random numbers in the range of the
average of smallest 5% of the data ± sd. Differences between each time point and no-enzyme
control were analyzed for statistical significance by multiple t-test. When compared to the con-
trol reaction, peptide cleavage products with>10-fold change in peak area intensity and p-
value <0.05 were identified and the peptide sequence corresponding to the P4 to P4’ subsite
positions were used to make IceLogo frequency plots [40]. Mass spectrometry data and results
can be accessed here: ftp://massive.ucsd.edu/MSV000081747.
Molecular modeling of SmSP2
A spatial model of the SmSP2 protease domain was constructed by homology modeling, as
described previously [37]. Briefly, the X-ray structures of human mannan-binding lectin serine
protease 1 (MASP-1) and bovine trypsin ((Protein Data Bank (PDB) entries: 3GOV and 1JRT,
respectively) were used as templates. The homology module generated by the MOE program
(Chemical Computing Group, Canada) was used to model the SmSP2 structure. The inhibitor
conformation was refined by applying the LigX module of the MOE and the final binding
mode of the inhibitor was selected by the best-fit model based on the London dG scoring func-
tion and the generalized Born method [37]. Molecular images were generated with UCSF Chi-
mera (http://www.cgl.ucsf.edu/chimera/).
Results
SmSP2 is a S1 family protease with a unique domain organization
The SmSP2 open reading frame consists of 1,506 bp that encode a protein of 501 amino acid
residues with a theoretical molecular mass of 58 kDa. The predicted signal sequence is 24 resi-
dues long and the amino acid sequence contains three potential N-glycosylation sites (Fig 1).
Based on sequence homology analysis, we describe SmSP2 as a multi-domain protein made up
of an N-terminal region (residues 25 to 110), a thrombospondin-1 type 1 repeat (TSR-1)
domain (residues 111 to 178) and a S1 family serine protease domain at the C-terminus (resi-
dues 201 to 501). The N-terminal region lacks significant similarity with other published pro-
tein sequences in databases. The striking feature of this region is the presence of a stretch of
histidine residues (the ‘His stretch’—residues 55 to 81) which suggests that SmSP2 may bind
metal ions.
The TSR-1 domain has been identified in multiple protein families and occurs in more
than 40 human proteins, e. g., thrombospondins, ADAMTS (A Disintegrin And
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Metalloproteinase with Thrombospondin Motif), properdin and some complement factors
[41]. It is known to mediate cell adhesion, protein-protein interactions, glycosaminoglycan
binding and inhibit angiogenesis [42, 43]. The TSR-1 of SmSP2 consists of about 60 residues
and its sequence contains all of the important conserved features of TSR-1 domains (S1 Fig): a
cysteine residue pattern and conservation of tryptophan and arginine residues forming so
called W and R layers [44].
The catalytic protease domain of SmSP2 belongs to the S1 family of serine proteases and
has about 30% identity with other members of this family (S2 Fig). The protease domain of
SmSP2 possesses a catalytic triad of His246, Asp311 and Ser447 (corresponding to amino acid
residues 57, 102 and 195 by standard chymotrypsinogen numbering), which is typical of S1
family proteases. In addition, the amino acids surrounding the catalytic-triad residues have the
highest sequence identity with other S1 family enzymes (S2 Fig). Cysteine residues in the cata-
lytic domain form four conserved disulfide bonds that can be predicted by the alignment with
the solved crystal structures of S1 family proteases (S2 Fig). Moreover, an additional cysteine
residue, Cys311, is likely to form a disulfide bond with a Cys188 in the N-terminal region. An
analogous disulfide bond is described, for example, in bovine chymotrypsinogen, human plas-
min, urokinase (uPA), tissue plasminogen activators (tPA) and MASP-1. In bovine trypsin,
Asp189 is located at the bottom of the S1 binding site and determines the trypsin-like specific-
ity for substrates with Arg/Lys in the P1 position [45]. This residue is conserved in the
sequence of SmSP2 (Asp441). When compared to bovine chymotrypsin, the S1 family holo-
type protease [46], SmSP2 has three insertions (S2 Fig) located between residues 222 and 226
(insertion-222), 251 and 268 (insertion-251), and between residues 358 and 400 (insertion-
358). Whereas protein sequences corresponding to the short insertions-222 and -251 are
found in uPA/tPA and MASP1, respectively, the long insertion-358 is unique to SmSP2.
SmSP2 orthologs are found in: (i) other schistosome species—S. japonicum (GenBank:
AAW24683.1) and S. haematobium (XP_012796372.1) sharing 80% and 78% sequence iden-
tity, respectively; (ii) other trematodes, including, Fasciola hepatica (identified in the transcrip-
tome database [47] - 53% identity), Opisthorchis viverrini (XP_009167273.1–49% identity),
Clonorchis sinensis (GAA32831.2–47% identity); and (iii) the sequences of cestodes such as
Hymenolepis microstoma (CDS25513.1), Echinococcus multilocularis (CDI97096.1), Echinococ-
cus granulosus (CDI97096.1), and Taenia solium (ADP89566.1) sharing 27–39% identities (S3
Fig). All of the ortholog sequences contain the TSR-1 and protease domains, however, they dif-
fer in the N-terminal region in length and the presence of the His stretch that is unique to
trematodes. Moreover, the insertion-358 in the cestode sequences is shorter and contains two
additional Cys residues that might potentially form a disulfide stabilizing this structure (S3
Fig). To conclude, SmSP2 and its orthologs are serine proteases with unique domain organiza-
tion found exclusively in the phylum Platyhelminthes.
Homology model of SmSP2 reveals the trypsin-like active site
pocket shielded by additional loops
A spatial model of the SmSP2 protease domain was constructed by homology modelling to
provide a structural framework to analyze structure-activity relationships. The X-ray structure
of bovine trypsin (PDB code 1JRT) and human MASP-1 (PDB code 3GOV) were used as tem-
plates. Fig 2A shows that the SmSP2 protease domain has the conserved architecture of S1
family proteases which consists of two six-stranded β-barrel domains packed against each
other. The catalytic amino acid residues, His246, Asp311 and Ser447 are located at the junction
between these β-barrel domains. The major sequence insertions in SmSP2 compared to trypsin
are located at surface-exposed loops surrounding the substrate binding region (Fig 2B).
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SmSP2 insertions-222 and -251 are located on the top of the loops B and A, respectively (Per-
ona and Craik nomenclature [48]). Their structural analogs can be found in the structure of
the MASP-1 catalytic domain where they putatively interact with substrates [49]. The inser-
tion-358 containing 43 residues are located at loop D; however, it has no structural analog in
the PDB database (www.rcsb.org) to serve as a template for modeling. The secondary structure
prediction did not reveal any conformational element in the loop, suggesting an unstructured
character and flexibility that might be involved in interactions during substrate binding.
The ligand binding mode of the SmSP2 protease domain was further analyzed using leu-
peptin (N-acetyl-L-leucyl-L-leucyl-L-arginal), a transition-state analog protease inhibitor that
inhibits SmSP2 (Table 1). Leupeptin was docked into the SmSP2 active site based on the crys-
tallographic complex of this inhibitor with trypsin (PDB code 1JRT). The docking model (Fig
2) suggests that the arginal residue of the inhibitor forms a covalent hemi-acetal linkage with
the catalytic Ser447 whereas leupeptin’s side chain binds to a deep negatively charged S1 sub-
site pocket containing Asp441 at the bottom. This type of S1 binding subsite is the primary
substrate specificity determinant of trypsin-type proteases and responsible for a substrate/
inhibitor preference for basic residues at the P1 position [45].
To conclude, the model of the SmSP2 protease domain indicates that it is a S1 family prote-
ase with an trypsin-like substrate binding groove; shielded by surface exposed loops that sur-
round the active site, namely, insertions-222 and -358, may modulate SmSP2’s selectivity.
Recombinant expression of SmSP2 and identification of native SmSP2
The protease domain of SmSP2 (rSmSP2, residues 183–501) was expressed in P. pastoris and
purified. The active enzyme cleaved Z-F-R-AMC and migrated on SDS-PAGE as a single band
of approximately 28 kDa (Fig 3A), consistent with the expected molecular mass of 30 kDa.
Fig 2. Homology model of the SmSP2 protease domain. The model was built using as a template the X-ray structures of bovine trypsin (PDB 1JRT) and human
MASP-1 (PDB 3GOV). (A) A superposition of the SmSP2 model (magenta), the bovine trypsin (green) and MASP-1 (cyan) crystal structures in a cylinder
representation. (B) A view from the top on the SmSP2 active site with covalently bound substrate-like inhibitor leupeptin (N-acetyl-L-leucyl-L-leucyl-L-argininal).
Carbon atoms of leupeptin are yellow; heteroatoms have the standard color coding (N, blue; O, red). SmSP2 catalytic residues are green. The active site is partially
blocked by loops A, B and D (magenta) that are formed by insertions in SmSP2 sequence compared to trypsin sequence. (C) A surface representation of the SmSP2
active site colored by electrostatic potential (at a scale from -10 kT/e (red) to +10 kT/e (blue)). Inhibitor leupeptin is colored as in (B).
https://doi.org/10.1371/journal.pntd.0006446.g002
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rSmSP2 was visualized using the activity-based probe Bodipy-F-P-R-Cmk (BoRC) (Fig 3A)
[35]; labeling by the probe was prevented by pre-incubation of the enzyme with the serine pro-
tease inhibitor, Pefabloc SC. Rabbit polyclonal antibodies, raised against the SmSP2 protease
domain expressed in E. coli, reacted with the rSmSP2 by immunoblotting (Fig 3A). In homoge-
nates of adult schistosomes, the antibody recognized three bands of approximately 45, 28 and
15 kDa (Fig 3B), which correspond to the predicted mass of the SmSP2 precursor, the activated
SmSP2 protease domain without N-terminal domains and the two-chain form derived by fur-
ther processing, respectively. Based on its molecular size, we hypothesize that this form was
clipped in the insertion-358 loop D. Analogous immunoreactive bands were also demon-
strated in the ESP of adult schistosomes (Fig 3B), indicating that SmSP2 is released into the
host environment.
The full length SmSP2 sequence contains a stretch of histidine residues that may interact
with metal ions. Indeed, native SmSP2 from schistosome extracts bound to a Ni2+- affinity
chromatography column and eluted using imidazole in solution (S4 Fig). The eluate contained
the three forms of SmSP2 described above. The data also indicate that the activated and clipped
protease domains (28 and 15 kDa bands) are disulfide-linked to the N-terminal portion of the
molecule that contains the histidine stretch.
Substrate and inhibitor specificity classifies SmSP2 as a trypsin-
like enzyme
The substrate specificity of rSmSP2 expressed in P. pastoris was initially explored using a panel
of specific peptidyl fluorogenic substrates. Two sets of diagnostic protease substrates were
used: (i) substrates with a basic amino acid residue (Arg and Lys) at the P1 position that are
cleaved by trypsin-like serine proteases, and (ii) substrates containing bulky hydrophobic (Phe
and Tyr) or aliphatic residues (Val, Leu and Met) at P1 that are cleaved by chymotrypsin- or
elastase-like serine proteases, respectively [50]. The data show that rSmSP2 predominantly
hydrolyzed trypsin substrates (Fig 4A). Activity was greatest with Bz-F-V-R-AMC and
Z-R-R-AMC, whereas less activity was measured with Z-V-V-R-AMC, Z-V-P-R-AMC and
Z-R-R-AMC. The cleavage of related short substrates with free N-termini occurs only very
Fig 3. Preparation of recombinant SmSP2 and identification of native SmSP2. (A) The recombinant protease
domain of SmSP2 (rSmSP2) expressed in P. pastoris was resolved by SDS-PAGE and protein-stained or visualized by
polyclonal anti-rSmSP2 IgG. For in-gel activity-based labeling, rSmSP2 was incubated with the fluorescent active site
probe, BoRC, resolved by SDS-PAGE and visualized using a fluorescence scanner. The competitive labeling was
performed with the serine protease inhibitor, Pefabloc SC. (B) Protein extracts of S. mansoni adult worms and their
ESP were resolved by SDS-PAGE and visualized by the anti-rSmSP2 IgG.
https://doi.org/10.1371/journal.pntd.0006446.g003
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slowly (G-R-AMC) or not at all (R-R-AMC and R-AMC), suggesting that SmSP2 is not an
aminopeptidase trimming N-terminal residues of substrates. The chymotrypsin/elastase sub-
strates were not effectively hydrolyzed.
The pH activity profile of rSmSP2 was determined using the P-F-R-AMC and was similar
to that of the serine protease activity in the schistosome adult homogenate (Fig 4B). Effective
hydrolysis was observed between pH 6.0 and 10.0 with optimal activity around pH 8.0. No
SmSP2 activity was detected below pH 5.0, although rSmSP2 is stable above pH 4.0 (Fig 4C).
To detail the cleavage specificity of rSmSP2, two distinct methods for unbiased substrate
profiling were employed. First, a positional scanning-synthetic combinatorial library (PS-SCL)
[39] was used to analyze specificity at the substrate positions P1 to P4 (Fig 5A). The cleavage
map shows that rSmSP2 prefers basic residues (Lys and Arg) at the P1 position. The P2 and P3
positions display promiscuous specificity, although basic residues at the P2 position, and acidic
Fig 4. Substrate specificity and pH profile of SmSP2. (A) Activity of rSmSP2 was probed using a panel of peptidyl fluorogenic substrates
used to assay trypsin-like and chymotrypsin/elastase-like serine proteases. Substrate hydrolysis was measured in a kinetic assay at pH 8.0.
The mean values ± S.D. of three replicates are normalized to the maximum value. Amino acid residues at P1 and P2 positions are
highlighted by the grey bar. (B) The pH profiles of rSmSP2 and native SmSP2 activity in extracts of adult worms. Activity was measured in
a kinetic assay using the fluorogenic substrate P-F-R-AMC. The native activity (sensitive to the serine protease inhibitor Pefabloc SC) was
measured in the presence of 10 μM E-64 and 1 mM EDTA to prevent undesired proteolysis of the substrate by cysteine proteases and
metalloproteases, respectively. The mean values of three replicates, expressed as a percentage normalized to the highest value, are shown
(standard deviation values are within 5% of the mean). (C) The pH stability of rSmSP2. Activity of rSmSP2 was measured at pH 8.0 in a
kinetic assay as in (B) after incubation of the enzyme at pH 3 to 11 for different times. The mean values of three replicates, expressed as a
percentage normalized to activity of non-incubated rSmSP2, are shown.
https://doi.org/10.1371/journal.pntd.0006446.g004
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residues and Pro at the P3 position are unfavorable. Some degree of selectivity was measured
for Pro at P4. Second, a sensitive multiplex substrate profiling by mass spectrometry
(MSP-MS) was performed with a library of 228 tetradecapeptides [51] to analyze the subsites
on both sides of the scissile peptide bond (Fig 5B). The MSP-MS profile confirmed the strong
preference for Arg and Lys residues at the P1 position. At the primed sites, the preferred resi-
dues were Ser at the P10, Ala and Gly at P20 positions, respectively. Compared to human
plasma kallikrein and bovine trypsin, the MSP-MS cleavage profile of SmSP2 were similar (Fig
5D) with 28 identical cleavage sites. However, trypsin produced 26 unique cleavages compared
to 11 cleavages unique for rSmSP2 or plasma kallikrein. In general, cleaved peptide bonds
Fig 5. Substrate specificity of rSmSP2. (A) The P1 to P4 specificity of rSmSP2 was determined by a positional scanning-synthetic combinatorial library. The
X-axis indicates 20 amino acids held constant at each position (n is norleucine). The Y-axis represents activity related to the most preferred amino acid (100%).
(B) The P4 to P40 specificity profiles of rSmSP2, human plasma kallikrein, and bovine trypsin were obtained using a multiplex combinatorial library (MSP-MS).
The iceLogo substrate profiles were generated from the pattern of cleavage events after incubation with the 14-mer library. Amino acids that are most frequently
found at each position are shown above the horizontal line, whereas amino acids that less frequently observed are below. (C) Spatial distribution of cleavage sites
within the 14-mer peptide scaffold. (D) The Venn diagram shows the number of unique and shared cleavage sites.
https://doi.org/10.1371/journal.pntd.0006446.g005
Serine protease SmSP2 from Schistosoma mansoni
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006446 April 20, 2018 14 / 26
occurred away from the amino and carboxyl termini confirming endopeptidase mode of
action of all three analyzed enzymes (Fig 5C).
The inhibitor specificity of rSmSP2 was investigated using a panel of small molecule and
protein inhibitors (Table 1). rSmSP2 was highly sensitive to inhibitors of S1 family serine pro-
teases, including the small-molecules, Pefabloc SC, benzamidine, leupeptin, antipain, and
3,4-dichlorcoumarin, and the proteinaceous soybean trypsin (STI) and bovine pancreatic tryp-
sin inhibitors (BPTI). rSmSP2 was not affected by inhibitors of aspartic, cysteine and metallo-
proteases. Protein inhibitors of the serpin family inhibited rSmSP2 with variable efficiencies:
PAI-I, α-1-antitrypsin and anti-thrombin III, which interact with trypsin-like proteases, inhib-
ited rSmSP2 activity strongly, whereas the chymotrypsin protease inhibitor, α-1-antichymo-
trypsin, was weakly effective.
To summarize, SmSP2 hydrolyzes substrates as an endopeptidase and has a strict specificity
for basic residues at P1.
SmSP2 releases bradykinin from kininogen and activates plasmin
The activity of rSmSP2 towards host-derived macromolecular substrates was tested with sev-
eral human and bovine proteins. After incubation, the mixtures were subsequently analyzed
by SDS-PAGE (Fig 6A). No hydrolysis was observed for hemoglobin and serum albumin, the
two major protein components of vertebrate host blood. Also, neither immunoglobulin G nor
collagen was cleaved by rSmSP2. On the other hand, rSmSP2 completely hydrolyzed the blood
clotting protein, fibronectin. We also analyzed the processing of three blood proteins:
HMWK, tPA and human plasminogen.
Amino acid sequencing showed that HMWK was processed to the kininogen light chain
(Fig 6A), and that the heavy chain was completely fragmented. LC-MS/MS analysis of the reac-
tion mixture revealed the release of the HMWK-derived vasodilatory nonapeptide, bradykinin
(Fig 6B). To simulate the bradykinin release from HMWK precursor, we designed a synthetic
hexadecapeptide (Ac-SLMKRPPGFSPFRSSR-amide) designated extended bradykinin. This
peptide was derived from the HMWK sequence to contain processing sites; i.e., the bradykinin
sequence (RPPGFSPFR) was extended at the N- terminus by four additional HMWK residues
(SLMK) and three residues on C-terminus (SSR). After incubation of this peptide with
rSmSP2, the resulting fragments were separated by HPLC and the cleavage positions identified
by mass spectrometry. The precursor was cleaved between Lys-Arg and Arg-Ser bonds thereby
releasing bradykinin (Fig 6C). Synthetic bradykinin or kallidin (lysyl-bradykinin) were not
cleaved by rSmSP2. Also, rSmSP2 degraded vasopressin, a nonapeptide hormone that
increases arterial blood pressure by inducing vasoconstriction.
Next, we investigated whether living schistosomes produce a cleavage specificity similar to
that of SmSP2 when incubating with vasopressin or extended bradykinin in culture. Adult
schistosomes were incubated in the presence of the peptides and cleavage positions analyzed
by mass spectrometry (Fig 6C). Both peptides were cleaved when added to the cultivation
medium: vasopressin was inactivated by cleavage after penultimate Arg residue; extended bra-
dykinin was cleaved to release bradykinin, however, cleavage precursors extended in N- or C-
terminal direction were also identified. The fragmentation was significantly abolished in the
presence of a serine protease specific inhibitor Pefabloc. The identified cleavage positions in
the hormone sequences were identical with those obtained by in vitro fragmentation using
rSmSP2.
The processing of human plasminogen, the precursor of the main fibrinolytic protease
plasmin, by rSmSP2 was analyzed by SDS-PAGE and kinetic assay. Single chain plasminogen
was completely converted into plasmin, consisting of a heavy chain and light chain). This
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Fig 6. Processing of host-derived proteins and peptides by rSmSP2. (A) Human serum albumin (HSA), hemoglobin (Hb), immunoglobulin G (IgG), collagen type I
(Col I), fibronectin (Fbn) and high molecular weight kininogen (HMWK) were incubated for 16 h at pH 8.0 in the presence (+) or absence (-) of rSmSP2. The reaction
mixtures were subjected to SDS-PAGE and protein stained. (B) HMWK was incubated with rSmSP2 and the reaction mixture was subjected to LC-MS/MS analysis to
identify bradykinin peptide released from HMWK. (C) Peptide hormones were incubated with rSmSP2 or with live adults maintained in culture and the cleavage
positions (full triangles for rSmSP2, open triangles for adult schistosomes) were identified by mass spectrometry. Residues at the P1 position are in bold and the disulfide
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processing was not the result of the self-activation as it only occurred in the presence of
rSMSP2 (Fig 6D and 6E). SDS-PAGE analysis showed that SmSP2 processes single-chain tPA
into its two-chain form; the cleavage was associated with a ten-fold increase in tPA activity
(Fig 6F). tPA is the major physiological activator of plasminogen, thus the SmSP2 cleavage of
single chain tPA into its fully active two-chain form would result in more efficient plasmin
activation and in turn more effective fibrinolysis.
To conclude, SmSP2 cleaves several physiologically important blood proteins. Specifically,
it processes the extracellular matrix and blood clot component, fibronectin, activates the major
fibrinolytic enzyme, plasmin, and its activator, tPA, releases the vasodilatory peptide bradyki-
nin from its HMWK precursor and processes the vasoconstrictory peptide vasopressin.
SmSP2 is localized in the tegument, parenchyma and reproductive organs
of adult schistosomes
Indirect immunofluorescence microscopy on semi-thin sections using affinity purified poly-
clonal antibodies raised against rSmSP2 demonstrated that SmSP2 is expressed in distinct tis-
sues of adult worms (Fig 7 and S5 Fig). In males, SmSP2 was observed in the parenchyma,
tegument and in the tegumental surface membranes except the tubercles (for a detailed tegu-
mental localization, see S5 Fig). In females, SmSP2 was observed in parenchyma but not in the
tegument. In addition, intense staining was seen in the esophageal region of both genders, in
the testes of males and in the ovaria and vitellaria of females (Fig 7). SmSP2 was absent from
muscle, the tegumental tubercles, gastrodermis and gut lumen. Pre-immune serum was used
as a negative control (S6 Fig) and only faint background fluorescence was detected.
Discussion
Serine proteases of the S1 family are key factors of virulence for many parasitic helminths.
They contribute to parasite invasion, migration, nutrition and reproduction, and facilitate
adaption to and evasion of the host’s physiological and immune responses (for reviews see [12,
52]). Among serine proteases, most attention has been focused on S. mansoni cercarial elas-
tases as these enzymes are implicated in tissue invasion and migration into the definitive mam-
malian hosts [13, 53]; however, information regarding other SmSPs is limited. Recently, we
described the repertoire of non-cercarial elastase SmSPs by employing a series of genomic,
transcriptomic, functional proteomic and phylogenetic approaches [23].
Here, we focus on SmSP2 as it is the most abundantly expressed SP in the Schistosoma
blood-dwelling developmental stages [23]. The domain organization of SmSP2 is distantly
reminiscent of the modular architecture of host blood-clotting serine proteases. Specifically,
these enzymes contain a catalytic trypsin-like serine protease domain linked by disulfide
bonds to an N-terminal multi-domain region that is involved in ligand-binding and protein-
protein interactions [54]. SmSP2 also has unique features—an N-terminal region histidine
stretch and a TSR-1 domain. TSR-1 domains mediate cell adhesion, protein-protein inter-
actions and glycosaminoglycans binding [42, 43]. The histidine stretch may act as a metal
binding site for divalent metal ions, as we demonstrated in vitro using metal-affinity
connectivity of vasopressin is indicated. (D) Human plasminogen (PLG) was incubated in the presence or absence of rSmSP2 and the reaction mixture was analyzed at
different time points. Plasmin proteolytic activity generated during plasminogen processing by rSmSP2 was determined in a kinetic assay with Boc-V-L-K-AMC. Mean
values of triplicates are expressed relative to the maximum value (100%). The S.D. values of three replicates are within 10% of the mean. All experiments were performed
at least twice with similar results. (E) The processed forms were resolved by SDS-PAGE and visualized by protein staining. The positions for PLG, and plasmin (PL)
heavy and light chains are indicated. (F) Human tissue plasminogen activator (tPA) was incubated for 16 h at pH 8.0 in the presence/absence of rSmSP2 and analyzed by
SDS-PAGE with protein staining; proteolytic activity generated during tPA processing was monitored in a kinetic assay using Z-G-G-R-AMC. Mean values ± s.d. of
triplicates are expressed relative to the maximum value (100%). Two chain tPA is indicated with an arrow.
https://doi.org/10.1371/journal.pntd.0006446.g006
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chromatography to purify native SmSP2 from the adult schistosome homogenate. The TSR-1
domain is also present in the sequences of SmSP2 orthologs in other trematodes; cestodes
retain only the TSR-1 domain while the histidine stretch is unique to trematodes (S3 Fig).
Orthologous genes were not found in other organisms. Further research is needed to evaluate
the exact function of the N-terminal domains of SmSP2.
SmSP2 orthologs (termed mastins) are present in S. haematobium and S. japonicum. For S.
haematobium infections, mastin was identified in a protein array as an antigen targeted by a
protective IgG1 immune response in those individuals with acquired resistance and, therefore,
suggested as an attractive vaccine candidate [24]. This resistance is acquired after treatment
with PZQ and the consequent exposure of parasite antigens to the host immune system [55].
SmSP2 orthologs are also present in the larval stage (cysticercus) of the cestodes, Echinococcus
granulosus [56] and Taenia solium [57], and were identified as Antigen 5 excretory proteins
(Ag5). Ag5 proteins are major components of cyst fluid and are used in a serodiagnostic test
for cysticercosis [57, 58]. In comparison with SmSP2, the catalytic serine residue is replaced by
threonine and Ag5 proteins show only marginal proteolytic activity [56, 57].
Fig 7. SmSP2 immunolocalization in sections of adult S. mansoni. Semi-thin sections of adult S. mansoni males (A to C) and females (D to F) were probed with an
anti-SmSP2 IgG followed by reaction with an anti-rabbit Alexa 647-labeled secondary antibody (red). DAPI was used to label nuclear DNA (blue). The left columns
show merged fluorescent channels; in the right columns, the signal is merged with differential interference contrast. A strong SmSP2 signal (red) was detected in both
sexes in the parenchyma (p) and the esophageal region (er). A faint signal was noted in the ventral (vs) and oral suckers (os). No signal was detected in the gut
(asterisks), muscle (mu) or tegumental tubercles (tu). In males, SmSP2 signal also appears in the tegument (arrowhead) in the tegumental membrane surface (arrow)
and in the testes (te). In females, the signal is noted in the ovaries (ov) and vitellaria (vit). The scale bar represents 100 μm. A and D, reproductive organs; B and E,
tegumental cells; C and F, head.
https://doi.org/10.1371/journal.pntd.0006446.g007
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In adult S. mansoni, we demonstrate that SmSP2 is localized in the tegument. Treatment
with PZQ causes tegumental damage [59, 60] and thereby exposes schistosome antigens,
including SmSP2, to the host immune system [55]. The tegumental location may explain the
recognition of SmSP2 by sera of PZQ-treated individuals [24]. Also, the localization of SmSP2
to the esophagus may indicate that the enzyme facilitates some aspect of nutrition during the
ingestion of host proteins or is secreted. Indeed, we observed that SmSP2 is found in the ESP
as was noted in E. granulosus previously for Ag5 [58, 61]. In addition, SmSP2 and its S. japoni-
cum mastin ortholog were recently proteomically identified in exosome-like vesicles that are
secreted by parasite and putatively modulate host-parasite interactions [62–64]. Finally, apart
from a potential extracorporeal function, the protease domain of SmSP2 was localized to a
number of internal tissues, including the ovaries, testes, muscle and parenchyma, suggesting a
variety of functional roles.
To enzymatically characterize SmSP2, the protease domain was heterologously expressed in
P. pastoris and purified as an active protease. SmSP2 was subjected to a range of biochemical
analyses to determine its substrate and inhibitory specificity. SmSP2 was classified as a trypsin-
like enzyme as it cleaves various peptide substrates in an endopeptidolytic mode at the car-
boxyl terminus of Arg or Lys residues and was inhibited by inhibitors targeting trypsin-like
proteases such as leupeptin, benzamidine and antipain [65]. Consistent with this, systematic
cleavage specificity analysis with the positional-scanning and multiplex substrate libraries
revealed a preference for basic amino acids at P1. In agreement with the cleavage specificities,
the homology model of SmSP2 reveals that the S1 binding pocket has an architecture analo-
gous to vertebrate trypsins, including the critical Asp441 residue that defines the preference
for basic P1 residues [45].
Based on homology modeling, the SmSP2 protease domain contains a large 43 residue-long
insertion (at position 358) which is a unique structural feature of SmSP2 and its trematode
orthologs not present in other S1 family proteases. This insertion is localized in the vicinity of
the active site on the loop D (nomenclature according to Perona and Craik [48]). We demon-
strate that SmSP2 performs limited proteolysis to process a number of physiologically- relevant
host proteins: it degrades fibronectin, activates plasmin and tPA and releases bradykinin from
its precursor HMWK. SmSP2 is incapable of cleaving macromolecular substrates such as Hb,
BSA and IgG, which, for example, are cleaved by the gut-associated cysteine and aspartic pro-
teases [15, 16]. SmSP2 has a more narrow substrate specificity than trypsin, the S1 family
archetypal protease. In multiplex cleavage assays, trypsin cleaved more substrates than SmSP2.
It resulted in similar number of cleavages produced by trypsin in 15 min whereas 4 h was
required by SmSP2. A plausible explanation is that the B and D loop-insertions on SmSP2
limit the access of substrates to the active site resulting in the selective processing of conforma-
tionally compatible peptides. However, the insertion-D does not directly occlude the active
site subsites as this would confer an exopeptidase activity that is not observed for SmSP2.
Adult schistosomes can survive for decades in the host [66]. It is thought that these large
intravascular parasites manipulate the complex hemostatic system of the host at different levels
via bioactive molecules in the ESP or on the tegument [67]. However, the detailed molecular
processes underlying these survival mechanisms are not fully understood. Our work demon-
strates that SmSP2 is present in both the ESP and tegument. We show that SmSP2 possesses a
kallikrein-like activity as it cleaves the plasma protein kininogen to generate the peptide hor-
mone, bradykinin. Bradykinin is a potent vasodilator that decreases blood pressure and
increases vascular permeability [68]. Bradykinin also exerts anti-thrombogenic, anti-prolifer-
ative and anti-fibrogenic effects [69]. In a recent report, we demonstrated that living schisto-
somes cleave bradykinin and angiotensin I (converting this vasoconstrictor to the vasodilatory
angiotensin-(1–7)), and that the tegumental, S9 serine protease, SmPOP, is involved in that
Serine protease SmSP2 from Schistosoma mansoni
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006446 April 20, 2018 19 / 26
processing [37]. Moreover, SmSP2 inactivates vasopressin, a hormone that increases arterial
blood pressure by inducing vasoconstriction. It is, therefore, possible that both SmPOP and
SmSP2 modulate the parasite’s local vascular environment to the parasite’s benefit during its
residence and movement in the host’s blood vessels. Additionally, we show that the whole
schistosome parasite can cleave the vasopressin and release bradykinin from its synthetic pre-
cursor, when co-incubated in vitro. The activity is due to a serine protease(s) (possibly SmSP2)
that is most abundantly expressed serine protease in adult schistosome [23] as indicated by
mRNA expression levels, mass spectrometry and specific inhibition by a serine protease
inhibitor.
Fig 8. Model of how SmSP2 may interfere with the host’s hemostatic system. SmSP2, secreted from adult schistosomes or localized at the
surface, stimulates the degradation of blood clots (thrombolysis panel) by (i) activation of two critical components of the fibrinolytic system,
tissue plasminogen activator (tPA) and plasminogen, and (ii) direct degradation of the blood-clot component, fibronectin. SmSP2 modulates
vascular tone (vasoregulation panel) by processing bioactive peptide hormones. (i) It releases the vasodilatory bradykinin from kininogen
(HMWK) and (ii) degrades the vasoconstrictory peptide, vasopressin. Bradykinin may stimulate the release of tPA from vascular endothelial cells
(dashed line) which would promote fibrinolysis. SmSP2 may be regulated by plasminogen activator inhibitor-1 (PAI-1) that inhibits SmSP2
(Table 1).
https://doi.org/10.1371/journal.pntd.0006446.g008
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Due to their large size, adult schistosomes may alter or disrupt normal blood flow, and
damage the endothelium, which could lead to platelet activation and subsequently blood coag-
ulation [67]. However, blood clots are not observed around the parasites residing in the host
blood vessels and several mechanisms have been proposed with which schistosomes inhibit
blood clot formation and/or promote blood clot lysis [70]. Physiologically, the latter process
involves proteolytic degradation of fibrin that is mediated by plasmin. This central protease in
the fibrinolytic system is generated from its zymogen, plasminogen (PLG), by, for example, tis-
sue plasminogen activator (tPA). Based on our in vitro results, we propose here a new and
complex mechanism with which schistosomes employ SmSP2 to promote fibrinolysis at multi-
ple levels (Fig 8): 1) SmSP2 activates PLG to plasmin; this action can be accelerated by presen-
tation of PLG on tegumental receptors (e.g., enolase [71] of schistosomes); 2) SmSP2 processes
the single-chain tPA to the more potent double-chain tPA form [72] which would then cause
enhanced plasmin activation, 3) SmSP2 produces bradykinin that is known to stimulate the
release of tPA from the vascular endothelium [73]; and 4) SmSP2 directly degrades the blood
clot component fibronectin, which has also been recently shown for a tegumental calpain [74].
To conclude, we have expressed, and biochemical and functionally characterized the multi-
domain serine protease, SmSP2. The protease is a putative anti-hemostatic peculiar to platyhel-
minths, which are the only pathogens to express SmSP2 orthologs. Further research is needed
to evaluate the role of SmSP2 (and orthologs) in modulating host-parasite interactions and its
potential as a drug or vaccine candidate.
Supporting information
S1 Fig. Multiple sequence alignment of the TSR-1 domain of SmSP2 with selected TSR-1
domains of human proteins. Sequences are: TSP-1-1-3—thrombospondin-1 (TSP) type-1
domains 1, 2 and 3 (Uniprot accession number: P07996), properdin-TSR1-6—properdin
thrombospondin type-1 domains 1–6 (P27918), ADAMTS13 (Q76LX8), and spondin-TSP-1
—spondin-1 thrombospondin type-1 domain 1 (Q9HCB6). Cys residues are highlighted in
yellow, tryptophan substituents forming the W layer are in blue, and amino acid residues
forming the R layers are in green.
(TIF)
S2 Fig. Multiple sequence alignment of the SmSP2 protease domain with catalytic domains
of selected human and bovine S1 family proteases. Human proteases: mannan-binding lec-
tin serine protease 1 (MASP-1, Uniprot accession number: P48740), tissue plasminogen activa-
tor (tPA, P00750), urokinase plasminogen activator (uPA, P00749), plasmin (P00747),
kallikrein 1 (P06870) and matriptase (MTSP-1, Q9Y5Y6). Bovine proteases: cationic trypsin
(P00760) and chymotrypsin A (P00766). The catalytic triad residues (His, Asp, Ser) are red-
boxed; the critical Asp residue in the S1 subsite that accounts for trypsin-like activity is green-
boxed. Cys residues that are predicted to form disulfide bonds are indicated by the same color,
cyan Cys form interchain disulfide bond with domains not included in the alignment. Resi-
dues that are shared between sequences are shaded in grey. Residues forming SmSP2 inser-
tion-222, 251, and 358 are underlined. The upper line numbering is according to SmSP2, the
lower line numbering according to bovine chymotrypsinogen.
(TIF)
S3 Fig. Multiple sequence alignment of SmSP2 with orthologs from other platyhelminth
parasites. Trematode sequences: Schistosoma. japonicum (GenBank: AAW24683.1), Schisto-
soma haematobium (XP_012796372.1), Fasciola hepatica (sequence identified in the transcrip-
tome database (Young et al. (2010), Biotechnol Adv 28, 222–231), Opisthorchis viverrini
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(XP_009167273.1) and Clonorchis sinensis (GAA32831.2). Cestode sequences: Hymenolepis
microstoma (CDS25513.1), Echinococcus multiocularis (CDI97096.1), Echinococcus granulosus
(EUB58856.1) and Taenia solium (ADP89566.1). Predicted signal sequences are in blue, histi-
dine residues in the N-terminal region are in purple and the TSR-1 domain is in green. The
catalytic triad residues (His, Asp, Ser) are red-boxed, the critical Asp residue in S1 subsite that
accounts for trypsin-like activity is green-boxed. Cys residues in the TSR-1 domain are
highlighted in yellow and Cys residues in the protease domain are in cyan.
(TIF)
S4 Fig. Binding of native SmSP2 to a Ni2+-ion affinity column. A protein extract of adult
schistosomes (Extract) was applied to a HiTrap IMAC FF column containing immobilized Ni2+
ions and native SmSP2 eluted using 0.5 M imidazole. The extract, unbound material (FT) and
eluted material (Elution) were resolved by SDS-PAGE, electrophoretically transferred onto a
PVDF membrane and visualized by anti-rSmSP2 IgG.
(TIF)
S5 Fig. Detailed micrograph of SmSP2 localization in the tegument of adult male S. man-
soni. The tissue section was probed with anti-SmSP2 IgG followed by an anti-rabbit IgG Alexa
594-labeled secondary antibody (red). DAPI was used to label the nuclear DNA (blue). The
left image shows merged fluorescent channels; on the right, schematic depiction of the adult
schistosome surface; sm—surface membrane, tg—tegument, mu—muscle, tc—tegumental cell
(cyton), pa—parenchym.
(TIF)
S6 Fig. Pre-immune serum is not reactive. As a negative control, semi-thin sections of adult
S. mansoni males and females were probed with a pre-immune serum (A-F) followed by reac-
tion with an anti-rabbit IgG Alexa 647-labeled secondary antibody (red). DAPI was used to
label nuclear DNA (blue). The first and third columns show merged fluorescent channels; in
the second and fourth columns, the signal is merged with differential interference contrast.
(TIF)
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